A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors

被引：0
|
作者：
Yu, X. [1 ]
Zhang, J. [2 ]
Liu, R. [2 ]
Deng, Y. [3 ]
Cai, Y. [3 ]
Sun, Y. [4 ]
Dang, Q. [4 ]
Hong, W. [5 ]
Song, Z. [6 ]
Guo, S. [2 ,7 ]
Gao, S.
Su, W. [8 ]
Shi, M. [8 ]
Fan, S. [8 ]
Zhang, B. [8 ]
Pan, B. [8 ]
Ren, Y. [8 ]
Wang, J. [8 ]
Zhong, C. [8 ]
Ma, L. [8 ]
机构：
[1] Fudan Univ, Dept Pancreat Surg, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Oncol, Guangzhou, Peoples R China
[4] Shandong Canc Hosp & Inst, Phase Clin Study Ctr 1, Jinan, Peoples R China
[5] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Thorac Med Oncol, Canc Hosp, Hangzhou, Peoples R China
[6] Univ Chinese Acad Sci, Canc Hosp, Phase Clin Study Ward 1, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[7] Henan Univ Sci & Technol, Dept Med Oncol, Affiliated Hosp 1, Luoyang, Peoples R China
[8] HUTCHMED China Ltd, R&D, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
77MO
引用
收藏
页码：S1496 / S1497
页数：2
相关论文
共 50 条
  • [1] First-in-human study of HMPL-295, an ERK1/2 inhibitor, in patients with advanced solid tumors: Dose-escalation results of monotherapy
    Yu, Xianjun
    Zhang, Jian
    Sun, Yuping
    Deng, Yanhong
    Guo, Shuangshuang
    Hong, Wei
    Shi, Si
    Liu, Rujiao
    Gao, Shuiping
    Dang, Qi
    Zhang, Jianwei
    Su, Weiguo
    Shi, Michael
    Fan, Songhua
    Zhang, Bo
    Pan, Beiqing
    Jia, Xiaoyun
    Wang, Jian
    Zhong, Chen
    Ma, Luguang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Results of a first-in-human, dose-escalation phase 1 study of the ERK1/2 inhibitor ATG-017 in patients with advanced solid tumors
    Wahlroos, Sara
    Teng, Christina
    Tran, Ben
    Voskoboynik, Mark
    Gan, Hui Kong
    Spencer, Andrew
    Kudva, Anupa
    Song, Ming
    Lynch, Kevin
    Yu, Zhinuan
    Desai, Jayesh
    Lemech, Charlotte Rose
    Lifehouse, Chris O'Brien
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Infante, Jeffrey R.
    Mendelson, David S.
    Burris, Howard A., III
    Bendell, Johanna C.
    Tolcher, Anthony W.
    Gordon, Michael S.
    Gillenwater, Heidi H.
    Arastu-Kapur, Shirin
    Wong, Hansen L.
    Papadopoulos, Kyriakos P.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (02) : 216 - 224
  • [4] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Jeffrey R. Infante
    David S. Mendelson
    Howard A. Burris
    Johanna C. Bendell
    Anthony W. Tolcher
    Michael S. Gordon
    Heidi H. Gillenwater
    Shirin Arastu-Kapur
    Hansen L. Wong
    Kyriakos P. Papadopoulos
    Investigational New Drugs, 2016, 34 : 216 - 224
  • [5] First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT901 as monotherapy in patients with select advanced solid tumors
    Harvey, R. Donald
    Falchook, Gerald Steven
    Naqash, Abdul Rafeh
    Kim, Joseph W.
    Dowlati, Afshin
    Le Bruchec, Yvan
    Coudert, Isabelle
    Ervin-Haynes, Annette L.
    Sommerhalder, David
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
    Rodon, Jordi
    Tawbi, Hussein A.
    Thomas, Anne L.
    Stoller, Ronald G.
    Turtschi, Christian P.
    Baselga, Jose
    Sarantopoulos, John
    Mahalingam, Devalingam
    Shou, Yaping
    Moles, Melissa A.
    Yang, Lin
    Granvil, Camille
    Hurh, Eunju
    Rose, Kristine L.
    Amakye, Dereck D.
    Dummer, Reinhard
    Mita, Alain C.
    CLINICAL CANCER RESEARCH, 2014, 20 (07) : 1900 - 1909
  • [7] First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors
    Tianhong Li
    Patricia LoRusso
    Michael L. Maitland
    Sai-Hong Ignatius Ou
    Erkut Bahceci
    Howard A. Ball
    Jung Wook Park
    Geoffrey Yuen
    Anthony Tolcher
    Journal of Hematology & Oncology, 9
  • [8] First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors
    Li, Tianhong
    LoRusso, Patricia
    Maitland, Michael L.
    Ou, Sai-Hong Ignatius
    Bahceci, Erkut
    Ball, Howard A.
    Park, Jung Wook
    Yuen, Geoffrey
    Tolcher, Anthony
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [9] A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
    Carducci, Michael A.
    Wang, Ding
    Habermehl, Christina
    Bodding, Matthias
    Rohdich, Felix
    Lignet, Floriane
    Duecker, Klaus
    Karpenko, Oleksandr
    Pudelko, Linda
    Gimmi, Claude
    LoRusso, Patricia
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (08): : 1638 - 1647
  • [10] A first-in-human, open-label, dose-escalation study to investigate the safety and tolerability of CHC2014, a tropomyosin receptor kinase (TRK) inhibitor, in adult patients with advanced solid tumors
    Yun, T.
    Shin, S. J.
    Kim, D-W.
    Yun, C. H.
    Heo, S.
    Hyun, B.
    Kim, Y. S.
    Kim, J. S.
    Moon, Y. W.
    ANNALS OF ONCOLOGY, 2022, 33 : S20 - S20
12345